Fosfomycin tromethamine

CAS: 78964-85-9 F: C7H18NO7P W: 259.19

Fosfomycin (MK-0955) tromethamine is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibi

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Fosfomycin (MK-0955) tromethamine is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin tromethamine shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria[1][2].
Invitro	Fosfomycin tromethamine is an epoxy antibacterial agent. Compared with other antibacterial agents, it acts by inhibiting the early process of cell wall synthesis[1].Fosfomycin tromethamine has bactericidal activity against a variety of gram-negative and gram-positive pathogens, including broad-spectrum production β-Bacteria of lactamase and carbapenemase, and against S. aureus strains with an inhibition rate of 90%[1].Fosfomycin tromethamine displays extensive tissue penetration, can be used to research of infections of the CNS, soft tissues, bone, lungs, and abscesses[2].
In Vivo	Fosfomycin tromethamine (80 mg/kg; i.v.-i.v. or i.v.-p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes in rats[3].Pharmacokinetic of Fosfomycin Tromethamine in Rats[4]Dibekacin Dose (mg)
Name	Fosfomycin tromethamine
CAS	78964-85-9
Formula	C7H18NO7P
Molar Mass	259.19
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Dijkmans AC, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel). 2017 Oct 31;6(4). pii: E24. [2]. Falagas ME, et al. Fosfomycin. Clin Microbiol Rev. 2016 Apr. 29(2):321-47. [3]. Inouye S, et al. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J Pharmacobiodyn. 1982 Sep. 5(9):659-69. [4]. Inouye S, et al. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. J Pharmacobiodyn. 1982 Dec. 5(12):941-50.

Loteprednol Etabonate-d3